In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Pāpāmoa retiree Marion Henriksen was meant to be travelling in Germany and Austria with a friend. Instead, she had to cancel ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...